Legend Biotech (NASDAQ:LEGN) vs. Neuphoria Therapeutics (NASDAQ:NEUP) Head-To-Head Analysis

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Insider & Institutional Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Neuphoria Therapeutics and Legend Biotech”s top-line revenue, earnings per share and valuation.

Neuphoria Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Neuphoria Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Neuphoria Therapeutics and Legend Biotech’s net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings for Neuphoria Therapeutics and Legend Biotech, as reported by MarketBeat.com.

Neuphoria Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 92.31%. Legend Biotech has a consensus target price of $53.14, suggesting a potential upside of 178.09%. Given Legend Biotech’s stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Neuphoria Therapeutics.

Summary

Legend Biotech beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Legend Biotech

(Get Free Report)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.